BridgeMD
Compares treatment options for ERCP
Official title Indomethacin vs Diclofenac for Preventing PEP
ClinicalTrials.gov ID: NCT07071441
What this study is testing
What is Indomethacin 100 MG?
Indomethacin 100 MG is an investigational medicine, being studied as a potential treatment for ercp.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Preprocedural administration of rectal non-steroidal anti-inflammatory drugs (NSAIDs) was demonstrated to be an effective and convenient strategy for post-ERCP pancreatitis (PEP).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- 18-90 years old patients with native papilla who planned to undergo ERCP
You likely can't join if
- Previous biliary sphincterotomy and papillary large balloon dilation
- Planned for placements of pancreatic duct stents (eg. pancreatic duct strictures, planned ampullectomy)
- Allergy to NSAIDs
- The administration of NSAIDs within 7 days
- Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction [Cr \>1.4mg/dl=120umol/l]; presence of...
- Acute pancreatitis within 7 days before ERCP or acute pancreatitis with obvious Pancreatic edema and peripancreatic fluid collections
See the full eligibility criteria
- 18-90 years old patients with native papilla who planned to undergo ERCP
- Previous biliary sphincterotomy and papillary large balloon dilation
- Planned for placements of pancreatic duct stents (eg. pancreatic duct strictures, planned ampullectomy)
- Allergy to NSAIDs
- The administration of NSAIDs within 7 days
- Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction [Cr \>1.4mg/dl=120umol/l]; presence of coagulopathy before the procedure)
- Acute pancreatitis within 7 days before ERCP or acute pancreatitis with obvious Pancreatic edema and peripancreatic fluid collections
- Hemodynamical instability
- Pregnancy or lactation
- Unable to give informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Chongqing, Chongqing Municipality, China
- Xiamen, Fujian, China
- Harbin, Heilongjiang, China
- Kaifeng, Hennan, China
- Wuhan, Hubei, China
- Changsha, Hunan, China
- Jilin City, Jilin, China
- Xining, Qinghai, China
- Xi'an, Shaanxi, China
- Jinan, Shandong, China
- Shanghai, Shanghai Municipality, China
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Chongqing, Chongqing Municipality, China; Xiamen, Fujian, China; Harbin, Heilongjiang, China; Kaifeng, Hennan, China; Wuhan, Hubei, China and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.